Ionis Pharmaceuticals (IONS)

$36.15 +0.91 (2.58%)
Market Cap 5.61B
Revenue (ttm) 705.14M
Net Income (ttm) -453.90M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin -64.37%
Debt to Equity Ratio 0.00
Volume 1,621,600
Avg Vol 1,634,784
Day's Range N/A - N/A
Shares Out 159.16M
Stochastic %K 49%
Beta 0.18
Analysts Strong Sell
Price Target $56.59

Company Profile

Ionis Pharmaceuticals, Inc., a commercial-stage biotechnology company, provides RNA-targeted medicines in the United States. The company offers TRYNGOLZA reduces triglyceride levels in adults with familial chylomicronemia syndrome (FCS) and acute pancreatitis; WAINUA for the treatment of the polyneuropathy of hereditary transthyretin-medicated amyloidosis (ATTRv-PN) in adults; and SPINRAZA for pediatric and adult patients with spinal muscular atrophy (SMA). It also provides QALSODY for the treat...

Industry: Biotechnology
Sector: Healthcare
Phone: 760 931 9200
Address:
2855 Gazelle Court, Carlsbad, United States
Estimize
Estimize Jun. 17 at 5:00 PM
Wall St is expecting -0.26 EPS for $IONS Q2 [Reporting 07/31 BMO] http://www.estimize.com/intro/ions?chart=historical&metric_name=eps&utm_c
0 · Reply
FinJay
FinJay Jun. 17 at 4:57 PM
$IONS https://youtu.be/VNSLKNltJN4
0 · Reply
rubraquercus
rubraquercus Jun. 17 at 12:03 PM
$IONS
0 · Reply
Estimize
Estimize Jun. 16 at 1:01 PM
Wall St is expecting -0.26 EPS for $IONS Q2 [Reporting 07/31 BMO] http://www.estimize.com/intro/ions?chart=historical&metric_name=eps&utm_c
0 · Reply
LewisDaKat
LewisDaKat Jun. 15 at 7:25 PM
News out (IONS) Investment Report https://marketwirenews.com/news-releases/-ions-investment-report-7152846288242778.html $IONS
0 · Reply
FinJay
FinJay Jun. 13 at 3:41 AM
$IONS https://youtu.be/iq6bdxdItJ0
0 · Reply
JarvisFlow
JarvisFlow Jun. 12 at 1:42 PM
JP Morgan has updated their rating for Ionis Pharmaceuticals ( $IONS ) to Neutral with a price target of 48.
0 · Reply
Greenamay
Greenamay Jun. 9 at 3:49 PM
$IONS phoenix 🐦‍🔥 rising from the ashes?
2 · Reply
FinJay
FinJay Jun. 6 at 5:22 AM
$IONS https://youtu.be/iq6bdxdItJ0
0 · Reply
rubraquercus
rubraquercus Jun. 5 at 11:51 PM
$IONS this does not include expected milestones from partners
1 · Reply
Latest News on IONS
Ionis announces Dr. Richard Geary, chief development officer, to retire; Dr. Holly Kordasiewicz to assume role in January 2026

Jun 12, 2025, 9:00 AM EDT - 5 days ago

Ionis announces Dr. Richard Geary, chief development officer, to retire; Dr. Holly Kordasiewicz to assume role in January 2026

First patient dosed in pivotal Phase 3 REVEAL clinical study of ION582 in Angelman syndrome

Jun 11, 2025, 7:00 AM EDT - 7 days ago

First patient dosed in pivotal Phase 3 REVEAL clinical study of ION582 in Angelman syndrome

Ionis announces positive topline results from Essence study of olezarsen in people with moderately elevated triglycerides

May 19, 2025, 7:00 AM EDT - 4 weeks ago

Ionis announces positive topline results from Essence study of olezarsen in people with moderately elevated triglycerides

Ionis to host 2025 virtual Annual Meeting of Stockholders

May 6, 2025, 7:05 AM EDT - 6 weeks ago

Ionis to host 2025 virtual Annual Meeting of Stockholders

Ionis Pharmaceuticals, Inc. (IONS) Q1 2025 Earnings Call Transcript

Apr 30, 2025, 2:20 PM EDT - 6 weeks ago

Ionis Pharmaceuticals, Inc. (IONS) Q1 2025 Earnings Call Transcript

Ionis Pharmaceuticals Narrows Q1 Loss, Lifts Revenue Forecast While Drug Sales Surge

Apr 30, 2025, 2:05 PM EDT - 6 weeks ago

Ionis Pharmaceuticals Narrows Q1 Loss, Lifts Revenue Forecast While Drug Sales Surge

Ionis reports first quarter 2025 financial results

Apr 30, 2025, 7:00 AM EDT - 7 weeks ago

Ionis reports first quarter 2025 financial results

New Harris Poll findings reveal HAE patients are unsatisfied with current prophylactic treatment options, with over 90% interested in trying new therapies

Apr 29, 2025, 7:00 AM EDT - 7 weeks ago

New Harris Poll findings reveal HAE patients are unsatisfied with current prophylactic treatment options, with over 90% interested in trying new therapies

Ionis: Potentially A Great Time To Buy Ahead Of Q1 Earnings (Upgrade)

Apr 22, 2025, 2:12 PM EDT - 2 months ago

Ionis: Potentially A Great Time To Buy Ahead Of Q1 Earnings (Upgrade)

Ionis to host expert panel discussion on sHTG

Apr 3, 2025, 7:05 AM EDT - 2 months ago

Ionis to host expert panel discussion on sHTG

Ionis to present at upcoming investor conferences

Mar 31, 2025, 7:05 AM EDT - 2 months ago

Ionis to present at upcoming investor conferences

Ionis expands partnership with Sobi to include olezarsen commercialization outside the U.S.

Mar 26, 2025, 7:00 AM EDT - 3 months ago

Ionis expands partnership with Sobi to include olezarsen commercialization outside the U.S.

Ono Enters into License Agreement with Ionis Pharmaceuticals for Sapablursen for the Treatment of Polycythemia Vera

Mar 11, 2025, 6:00 PM EDT - 3 months ago

Ono Enters into License Agreement with Ionis Pharmaceuticals for Sapablursen for the Treatment of Polycythemia Vera

Ionis and Ono announce global license agreement for sapablursen in polycythemia vera

Mar 11, 2025, 6:00 PM EDT - 3 months ago

Ionis and Ono announce global license agreement for sapablursen in polycythemia vera

WAINZUA (eplontersen) approved in the EU for the treatment of hereditary transthyretin-mediated amyloidosis in adults with stage 1 or stage 2 polyneuropathy

Mar 10, 2025, 7:00 AM EDT - 3 months ago

WAINZUA (eplontersen) approved in the EU for the treatment of hereditary transthyretin-mediated amyloidosis in adults with stage 1 or stage 2 polyneuropathy

New positive donidalorsen data to be presented at AAAAI/WAO Joint Congress highlight sustained HAE attack rate reduction and disease control

Feb 20, 2025, 7:00 AM EST - 4 months ago

New positive donidalorsen data to be presented at AAAAI/WAO Joint Congress highlight sustained HAE attack rate reduction and disease control

Ionis Pharmaceuticals, Inc. (IONS) Q4 2024 Earnings Call Transcript

Feb 19, 2025, 4:10 PM EST - 4 months ago

Ionis Pharmaceuticals, Inc. (IONS) Q4 2024 Earnings Call Transcript

Ionis Pharmaceuticals Reports Strong Q4 Earnings After Recent FDA Approval

Feb 19, 2025, 2:40 PM EST - 4 months ago

Ionis Pharmaceuticals Reports Strong Q4 Earnings After Recent FDA Approval

Ionis Pharmaceuticals Q4 Revenue Growth Exceeds Guidance, Forecasts Over $600 Million In 2025 Sales

Feb 19, 2025, 12:11 PM EST - 4 months ago

Ionis Pharmaceuticals Q4 Revenue Growth Exceeds Guidance, Forecasts Over $600 Million In 2025 Sales

Ionis reports fourth quarter and full year 2024 financial results

Feb 19, 2025, 7:00 AM EST - 4 months ago

Ionis reports fourth quarter and full year 2024 financial results

Ionis to hold fourth quarter and full year 2024 financial results webcast

Feb 5, 2025, 7:05 AM EST - 4 months ago

Ionis to hold fourth quarter and full year 2024 financial results webcast

Amyloidosis Treatment Market Research by Treatment, Drug Class, End-User, and Region - Global Forecasts to 2034

Jan 15, 2025, 9:17 AM EST - 5 months ago

Amyloidosis Treatment Market Research by Treatment, Drug Class, End-User, and Region - Global Forecasts to 2034

Ionis enters new chapter in 2025 as commercial-stage biotech with multiple independent product launches anticipated and continued late-stage pipeline momentum

Jan 13, 2025, 8:00 AM EST - 5 months ago

Ionis enters new chapter in 2025 as commercial-stage biotech with multiple independent product launches anticipated and continued late-stage pipeline momentum

Ionis to present at 43rd Annual J.P. Morgan Healthcare Conference

Jan 8, 2025, 4:11 PM EST - 5 months ago

Ionis to present at 43rd Annual J.P. Morgan Healthcare Conference

Ionis Pharmaceuticals: Promising Growth From Tryngolza Approval

Dec 23, 2024, 7:30 AM EST - 6 months ago

Ionis Pharmaceuticals: Promising Growth From Tryngolza Approval

FDA Approves Ionis Pharmaceuticals' Rare Genetic Disease Therapy to Lower High-Level Of Fat In Blood

Dec 20, 2024, 7:24 AM EST - 6 months ago

FDA Approves Ionis Pharmaceuticals' Rare Genetic Disease Therapy to Lower High-Level Of Fat In Blood

TRYNGOLZA™ (olezarsen) approved in U.S. as first-ever treatment for adults living with familial chylomicronemia syndrome as an adjunct to diet

Dec 19, 2024, 6:28 PM EST - 6 months ago

TRYNGOLZA™ (olezarsen) approved in U.S. as first-ever treatment for adults living with familial chylomicronemia syndrome as an adjunct to diet

US FDA approves Ionis Pharma's genetic disorder drug

Dec 19, 2024, 5:18 PM EST - 6 months ago

US FDA approves Ionis Pharma's genetic disorder drug

Ionis Pharmaceuticals, Inc. (IONS) Q3 2024 Earnings Call Transcript

Nov 6, 2024, 2:35 PM EST - 7 months ago

Ionis Pharmaceuticals, Inc. (IONS) Q3 2024 Earnings Call Transcript

Ionis Announces Pivotal Phase 3 Trial Design for ION582 in Angelman Syndrome

Nov 6, 2024, 7:01 AM EST - 7 months ago

Ionis Announces Pivotal Phase 3 Trial Design for ION582 in Angelman Syndrome

Ionis reports third quarter 2024 financial results

Nov 6, 2024, 7:00 AM EST - 7 months ago

Ionis reports third quarter 2024 financial results

Ionis announces FDA acceptance of New Drug Application for donidalorsen for prophylactic treatment of HAE

Nov 4, 2024, 9:44 AM EST - 8 months ago

Ionis announces FDA acceptance of New Drug Application for donidalorsen for prophylactic treatment of HAE

Ionis Pharmaceuticals: Catalysts Due In 2025/2026 Are Extremely Compelling

Oct 23, 2024, 4:25 PM EDT - 8 months ago

Ionis Pharmaceuticals: Catalysts Due In 2025/2026 Are Extremely Compelling

Ionis to hold third quarter 2024 financial results webcast

Oct 23, 2024, 7:05 AM EDT - 8 months ago

Ionis to hold third quarter 2024 financial results webcast

WAINZUA (eplontersen) recommended for approval in the EU by CHMP for the treatment of adults with polyneuropathy associated with hereditary transthyretin-mediated amyloidosis

Oct 21, 2024, 2:08 AM EDT - 8 months ago

WAINZUA (eplontersen) recommended for approval in the EU by CHMP for the treatment of adults with polyneuropathy associated with hereditary transthyretin-mediated amyloidosis

New positive donidalorsen data to be presented at 2024 American College of Allergy, Asthma & Immunology (ACAAI) Annual Scientific Meeting

Oct 3, 2024, 7:00 AM EDT - 9 months ago

New positive donidalorsen data to be presented at 2024 American College of Allergy, Asthma & Immunology (ACAAI) Annual Scientific Meeting

Zilganersen granted U.S. FDA Fast Track designation for people living with Alexander disease

Oct 1, 2024, 7:00 AM EDT - 9 months ago

Zilganersen granted U.S. FDA Fast Track designation for people living with Alexander disease

Rubrik Reports Q2 Results, Joins Ionis Pharmaceuticals, Hewlett Packard Enterprise And Other Big Stocks Moving Lower In Tuesday's Pre-Market Session

Sep 10, 2024, 8:32 AM EDT - 10 months ago

Rubrik Reports Q2 Results, Joins Ionis Pharmaceuticals, Hewlett Packard Enterprise And Other Big Stocks Moving Lower In Tuesday's Pre-Market Session

HPE RBRK

Ionis announces pricing of $500.3 million public offering

Sep 9, 2024, 9:10 PM EDT - 10 months ago

Ionis announces pricing of $500.3 million public offering

Ionis announces proposed public offering of common stock

Sep 9, 2024, 4:20 PM EDT - 10 months ago

Ionis announces proposed public offering of common stock

Ionis Pharmaceuticals: Harnessing RNA-Targeted Therapies For Long-Term Shareholder Value

Aug 11, 2024, 6:51 AM EDT - 11 months ago

Ionis Pharmaceuticals: Harnessing RNA-Targeted Therapies For Long-Term Shareholder Value

Ionis Pharmaceuticals, Inc. (IONS) Q2 2024 Earnings Call Transcript

Aug 1, 2024, 4:52 PM EDT - 11 months ago

Ionis Pharmaceuticals, Inc. (IONS) Q2 2024 Earnings Call Transcript

Ionis reports second quarter 2024 financial results

Aug 1, 2024, 7:00 AM EDT - 11 months ago

Ionis reports second quarter 2024 financial results

Alcyone Therapeutics Announces Continued Enrollment Approval from FDA of the PIERRE Pivotal IDE Clinical Study of the ThecaFlex DRx™ System for Administration of nusinersen

Jul 31, 2024, 9:00 AM EDT - 11 months ago

Alcyone Therapeutics Announces Continued Enrollment Approval from FDA of the PIERRE Pivotal IDE Clinical Study of the ThecaFlex DRx™ System for Administration of nusinersen

BIIB

Ionis Pharmaceuticals, Inc. (IONS) HALOS Study of ION582 in Angelman Syndrome - (Transcript)

Jul 22, 2024, 1:15 PM EDT - 11 months ago

Ionis Pharmaceuticals, Inc. (IONS) HALOS Study of ION582 in Angelman Syndrome - (Transcript)

Ionis' Rare Development Disorder Drug Candidate 'Could Be Differentiated' From Peer Ultragenyx: Analyst

Jul 22, 2024, 1:04 PM EDT - 11 months ago

Ionis' Rare Development Disorder Drug Candidate 'Could Be Differentiated' From Peer Ultragenyx: Analyst

RARE

Ionis announces positive detailed results from the HALOS Study of ION582 in people with Angelman syndrome

Jul 22, 2024, 7:00 AM EDT - 11 months ago

Ionis announces positive detailed results from the HALOS Study of ION582 in people with Angelman syndrome

Ionis to hold second quarter 2024 financial results webcast

Jul 19, 2024, 8:24 AM EDT - 11 months ago

Ionis to hold second quarter 2024 financial results webcast

Ionis completes enrollment in pivotal trial evaluating zilganersen in people living with Alexander disease

Jul 18, 2024, 7:00 AM EDT - 11 months ago

Ionis completes enrollment in pivotal trial evaluating zilganersen in people living with Alexander disease

Ionis announces webcast to report HALOS study results for ION582 in Angelman syndrome

Jul 8, 2024, 7:05 AM EDT - 1 year ago

Ionis announces webcast to report HALOS study results for ION582 in Angelman syndrome

Estimize
Estimize Jun. 17 at 5:00 PM
Wall St is expecting -0.26 EPS for $IONS Q2 [Reporting 07/31 BMO] http://www.estimize.com/intro/ions?chart=historical&metric_name=eps&utm_c
0 · Reply
FinJay
FinJay Jun. 17 at 4:57 PM
$IONS https://youtu.be/VNSLKNltJN4
0 · Reply
rubraquercus
rubraquercus Jun. 17 at 12:03 PM
$IONS
0 · Reply
Estimize
Estimize Jun. 16 at 1:01 PM
Wall St is expecting -0.26 EPS for $IONS Q2 [Reporting 07/31 BMO] http://www.estimize.com/intro/ions?chart=historical&metric_name=eps&utm_c
0 · Reply
LewisDaKat
LewisDaKat Jun. 15 at 7:25 PM
News out (IONS) Investment Report https://marketwirenews.com/news-releases/-ions-investment-report-7152846288242778.html $IONS
0 · Reply
FinJay
FinJay Jun. 13 at 3:41 AM
$IONS https://youtu.be/iq6bdxdItJ0
0 · Reply
JarvisFlow
JarvisFlow Jun. 12 at 1:42 PM
JP Morgan has updated their rating for Ionis Pharmaceuticals ( $IONS ) to Neutral with a price target of 48.
0 · Reply
Greenamay
Greenamay Jun. 9 at 3:49 PM
$IONS phoenix 🐦‍🔥 rising from the ashes?
2 · Reply
FinJay
FinJay Jun. 6 at 5:22 AM
$IONS https://youtu.be/iq6bdxdItJ0
0 · Reply
rubraquercus
rubraquercus Jun. 5 at 11:51 PM
$IONS this does not include expected milestones from partners
1 · Reply
rubraquercus
rubraquercus Jun. 5 at 11:25 PM
$IONS 10 phase 3 trials
0 · Reply
rubraquercus
rubraquercus Jun. 5 at 10:41 PM
$IONS he said 5 billion annual run rate in 2 years?
0 · Reply
rubraquercus
rubraquercus Jun. 5 at 10:29 PM
$IONS and a better sound system
0 · Reply
rubraquercus
rubraquercus Jun. 5 at 10:04 PM
$IONS This guy needs some public speaking speech classes
1 · Reply
GMH21
GMH21 Jun. 2 at 6:05 PM
$IONS Thinking the Donidalorsen PDUFA date will be a pretty significant catalyst. Superior efficacy and ease of administration, plus 91% of patients looking for better options that current treatment. $2B market for HAE.
1 · Reply
Wyckly670
Wyckly670 May. 30 at 2:18 PM
$PGEN PDUFA 08/27 - potential breakout with LPS at weekly MA50 + pivot point. Upcoming PDUFA's: $VSTM $KALV $IONS $THTX ...
1 · Reply
BioTechHealthX
BioTechHealthX May. 26 at 4:38 AM
$IONS With rising revenues, blockbuster partnerships, & upcoming product launches, Ionis offers strong growth potential for biotech investors. https://biotechhealthx.com/biotech-news/ionis-pharmaceuticals-ions-is-a-bullish-biotech-bet-in-2025/
0 · Reply
FinJay
FinJay May. 21 at 4:57 AM
$IONS https://youtu.be/iq6bdxdItJ0
0 · Reply
JarvisFlow
JarvisFlow May. 20 at 11:00 AM
HC Wainwright & Co. has updated their rating for Ionis Pharmaceuticals ( $IONS ) to Buy with a price target of 50.
0 · Reply
Rage_Against_The_Machine
Rage_Against_The_Machine May. 19 at 11:20 AM
$IONS delivers again - olezarsen shows 61% triglyceride reduction in 1,478-patient Essence study with clean safety profile. Pivotal Phase 3 data due Q3 could unlock $2B+ sHTG market. Street's 71% upside target looks plausible if execution holds, but remember this burns $200M/quarter. https://www.sec.gov/Archives/edgar/data/874015/000114036125019620/ef20049265_8k.htm
1 · Reply
DonCorleone77
DonCorleone77 May. 19 at 11:12 AM
$IONS Ionis Pharmaceuticals announces topline results from Essence study of olezarsen Ionis Pharmaceuticals announced topline results from the Essence study of olezarsen in people with moderate hypertriglyceridemia with or at risk for atherosclerotic cardiovascular disease. Nearly all the participants were on current standard of care lipid-lowering medicines. The trial met its primary endpoint with a statistically significant placebo-adjusted 61% and 58% reduction in triglyceride levels at six months with the 80 mg and 50 mg monthly doses, respectively. Olezarsen also met all key secondary endpoints in the study. The vast majority of participants reached less than150mg/dL, reflecting a reduction to normal TG levels. Olezarsen demonstrated a favorable safety and tolerability profile in the study. Ionis plans to submit an abstract for presentation at an upcoming scientific conference. Data from the pivotal Phase 3 CORE and CORE2 studies evaluating olezarsen for the treatment of severe hypertriglyceridemia are expected in Q3. Olezarsen demonstrated a favorable safety and tolerability profile in the study. The most common treatment-emergent adverse event that occurred more frequently than placebo in the olezarsen groups was injection site reactions, with the majority being mild in severity.
0 · Reply
Estimize
Estimize May. 12 at 1:03 PM
Wall St is expecting -0.47 EPS for $IONS Q2 [Reporting 07/31 BMO] http://www.estimize.com/intro/ions?chart=historical&metric_name=eps&utm_c
0 · Reply